New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 13, 2012
10:24 EDTPPL, CELG, NOK, ABC, JBHT, ITW, AMTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Tower (AMT) downgraded to Neutral from Overweight at Piper Jaffray... AmerisourceBergen (ABC) downgraded to Equal Weight from Overweight at Morgan Stanley... Celgene (CELG) downgraded to Hold from Buy at Auriga... Illinois Tool Works (ITW) downgraded to Underweight from Equal Weight at Morgan Stanley... Nokia (NOK) downgraded to Equal Weight from Overweight at Barclays... PPL Corp. (PPL) downgraded to Buy from Conviction Buy at Goldman... J.B. Hunt (JBHT) downgraded to Neutral from Buy at Sterne Agee.
News For AMT;ABC;CELG;ITW;NOK;PPL;JBHT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 21, 2014
06:04 EDTCELGCelgene receives positive CHMP opinion for OTEZLA
Celgene announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, or PDE4, in two therapeutic indications, for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or, who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light, or PUVA; alone or in combination with Disease Modifying Antirheumatic Drugs, or DMARD, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
November 19, 2014
13:10 EDTAMTDISH, Globalstar climb as wireless spectrum bids reportedly jump
Subscribe for More Information
09:39 EDTCELGCelgene management to meet with ISI Group
Subscribe for More Information
07:30 EDTAMTMorgan Stanley to hold a conference
European Technology, Media & Telecoms Conference is being held in Barcelona, Spain on November 19-21.
07:19 EDTAMTSpectrum auction positive for DISH, Globalstar, says JPMorgan
JPMorgan notes the AWS-3 spectrum auction continued on Tuesday with the aggregate value of licenses with bids at $16.4B, up from Monday's $8.9B and compared to the reserve price of $10.6B that the FCC set for the entire auction. The firm views the rise in prices as negative for telecom carriers that are spending more than expected, namely AT&T (T) and Verizon (VZ), and possibly T-Mobile (TMUS) and US Cellular. It views the prices as positive for independent spectrum owners like DISH (DISH) and Globalstar (GSAT), as well as tower companies American Tower (AMT), SBA Communications (SBAC) and Crown Castle (CCI).
November 18, 2014
10:55 EDTNOKNokia shares higher after announcing N1 Android tablet
Subscribe for More Information
07:37 EDTPPLNorthWestern closed $900M purchase of eleven hydroelectric facilities from PPL
Subscribe for More Information
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
06:46 EDTNOKMicrosoft could spin off Nokia MixRadio, TechCrunch reports
According to sources, Microsoft (MSFT) is considering spinning off Nokia MixRadio, the music streaming service it acquired as part of its takeover of Nokia's (NOK) Devices and Services unit, TechCrunch reports. Microsoft is reportedly seeking investors for Nokia MIxRadio, and the potential spin-off is said to be making "good progress." Reference Link
06:28 EDTNOKNokia to launch Android tablet, FT reports
Subscribe for More Information
November 17, 2014
10:02 EDTNOKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:25 EDTNOKNokia potential to grow businesses increases confidence, says Canaccord
Subscribe for More Information
07:16 EDTCELGMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
05:46 EDTNOKNokia downgraded to Underperform from Market Perform at Raymond James
Raymond James downgraded Nokia to Underperform citing high expectations for Technology unit and Networks sales growth. The firm thinks shares at current levels are pricing in a doubling of Technology unit sales.
November 14, 2014
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:23 EDTNOKNokia to host Capital Markets Day
Subscribe for More Information
November 13, 2014
18:40 EDTABCOn The Fly: After Hours Movers
UP AFTER EARNINGS: TubeMogul (TUBE), up 12.4%... Weibo (WB), up 3.2%... Nordstrom (JWN), up 3.1%. ALSO HIGHER: Geron (GERN), up 30.7% after announcing a global strategic collaboration with Janssen Biotech... Baker Hughes (BHI), up 16.2% following reports that the company is in talks to be acquired by Halliburton (HAL)... Halliburton is up 1.4%... Pandora (P), up 4% after announcing a conference call to discuss Web IV proceeding... AmerisourceBergen (ABC), up 1.1% after being awarded a $4.06B government contract. DOWN AFTER EARNINGS: Retrophin (RTRX), down 6.6%... Phoenix New Media (FENG), down 8.4%... Voxeljet AG (VJET), down 8.6%... Intrexon (XON), down 1.1%... Youku Tudou (YOKU), down 5.7%... Applied Materials (AMAT), down 2.5%. ALSO LOWER: Puma Biotechnology (PBYI), down 6.9% following PB272 Phase II Trial results... EnLink Midstream (ENLK), down 4.8% after filing to sell 10.5M common units representing limited partners.
17:38 EDTABCAmerisourceBergen awarded $4.06B government contract
Subscribe for More Information
09:16 EDTABCAmerisourceBergen management to meet with Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use